Navigation Links
VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting

rrent expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to Lenocta(TM) for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize Lenocta(TM) for the treatment of leishmaniasis or any other indication, or that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM) and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    Contact information:

    Daniel Greenleaf                     Brian Lenz

    President and CEO                    Chief Financial Officer

    908-766-4400 ext. 115                908-766-4400 ext. 117

          

dan.greenleaf@vioquestpharm.com brian.lenz@vioquestpharm.com

CONTACT: Daniel Greenleaf, President and CEO, +1-908-766-4400
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/1/2014)... , Oct. 1, 2014   Cypher Genomics, Inc., ... of J. Patrick Ravenel as chief technology ... software and systems experience and a proven track record ... "Patrick has been recognized as a ... systems and is known industry-wide for delivering innovative products ...
(Date:10/1/2014)... Mass. , Oct. 1, 2014   ... AEX: PHIA) today announced its eCareCoordinator and eCareCompanion ... U.S. Food and Drug Administration (FDA). A part ... telehealth programs , eCareCoordinator and eCareCompanion are focused ... the first clinical applications to be available through ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Further data shows PegIFN-λ,s ... New data presented at the International ... revolution in HCV treatment. The much anticipated data from ... combinations of antivirals offer the hope of shorter, more ...
... On Thursday, April 19, 2012, at 8:30 a.m. Eastern/2:30 ... Inc.,s (CTI) (NASDAQ and MTA: CTIC) management team will ... Numbers Thursday, April 19 8:30 a.m. ... (US Participants) 1-480-629-9692 (International) Call-back numbers for ...
Cached Medicine Technology:New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 2New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 3New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 4New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 5New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 6New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients 7
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
(Date:10/1/2014)... at the occasion of the Leishmaniasis East Africa ... and international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and ... were presented to key decision makers in order ... with the combination of Sodium Stibogluconate and Paromomycin ...
(Date:10/1/2014)... 2014 October is national Breast Cancer ... detection plans while raising money for breast cancer research. ... Awareness Month in the effort to find a ... the importance of having access to clean, healthy water. ... linked to certain forms of cancer. , The ...
(Date:10/1/2014)... HILLS, CA (PRWEB) October 01, 2014 ... cosmetic dentists and prosthodontists, is traveling to Chennai, ... Oral Implantologists on Oct. 2 and 3. , Dr. ... in Woodland Hills and Oxnard, Calif., and one of ... in teeth restoration and replacement. He is speaking to ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Two bicyclists ... take them across the country in an effort to ... military families. The cyclists, a father-daughter team, plan ... beginning in Blaine, Washington and finishing in Key West ... Hope For The Warriors®, a national nonprofit organization that ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... medical researchers in the United States has discovered what may ... cancer.// ,The scientists from the University of ... halting the activity of a single enzyme called aldose reductase. ... of biochemical signals that promotes inflammation and colon cancer cell ...
... of interest for post menopausal women with breast cancer ... Herceptin (trastuzumab) from Roche// and Arimidex (anastrozole) from AstraZeneca ... time by 4.8 months. ,A Phase III clinical ... the progression by just 2.4 months after which the ...
... people affected by chikungunya, a viral fever caused by mosquitoes//, ... the state government on the nature of the disease. ... not chikungunya. The government is doing its best to contain ... have asked people from other systems of medicines like Ayurveda ...
... an undiagnosed disorder and fighting to stay in Canada, has ... state after three years.// ,"I just hugged them... and ... parents landed at Vancouver airport last week. ,Dhaval ... Gujarat advised him to move after looking at his condition ...
... It was just weeks following the 9/11 attacks in ... offices of the news media and two US senators//. The ... five people and infected 17 others. , ,In a ... University of Georgia, teaming up with scientists at the federal ...
... and at times even forbid birthday cupcakes due to ... bring carrots," said Laura Ott, assistant to the superintendent.,A ... a sticker and a pencil instead of sweets from ... Unified School District, in Orange County, Calif., has restricted ...
Cached Medicine News:Health News:Indian with Rare Disorder Reunited with Family 2Health News:Cell-Wall Carbohydrate in Anthrax Bacterium Holds Promise for New Vaccines 2
Occluder and Maddox Rod...
Graham Field 10' Reversed Snellen Eye Chart....
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... on Optics can be useful in the ... help while normalizing blood sugar. Post cataract ... -provide magnification. Accommodative esotropia - address residual ... placement. Sunglasses - add bifocals. Specialty - ...
Medicine Products: